

Table. S1. The number of unique and total peptides for the supernatant of CdM<sup>CRTL</sup> and CdM<sup>SORA</sup> via LC-MS/MS analysis

Accession	Description	# unique peptides	# total peptides	# unique Peptides + sorafenib	# total Peptides + sorafenib
P07355	ANXA2	1	1	15	15
P00558	PGK1	0	0	9	9
P09211	GSTP1	2	2	9	9
P04083	ANXA1	1	1	8	8
P28482	MAPK1	0	0	8	10
P09429	HMGB1	1	1	4	5
Q01469	FABP5	0	0	4	4
P0DP23	CALM1	0	0	4	4
P07339	CTSD	0	0	4	4
P08758	ANXA5	1	1	4	5
Q99075	HBEGF	0	0	4	4
Q9UQ80	PA2G4	0	0	3	3
Q9Y376	CAB39	0	0	3	3
Q16270	IGFBP7	10	10	2	2
Q9Y5Z4	HEBP2	0	0	2	2
P18065	IGFBP2	0	0	1	1
Q04756	HGFAC	0	0	1	1

Abbreviation: CRTL, control; SORA, sorafenib; CdM, HUVECs conditional medium.